Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SCC77: Bloomage Bloomsurfact EncapCare RP Ensures 99% Dispersion of Anti-aging Ingredient
Details :
Product Name : Hyanutra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Lumenis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lumenis and Bloomage Biotech jointly released a new product - M22 medical wound dressing
Details : M22 medical wound dressing (sodium hyaluronate) is a versatile laser treatment system based on Lumenis' medical beauty concept of "30% Laser Treatment and 70% Postoperative care.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2023
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Lumenis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Hyanutra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zinc Hyaluronate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hybloom Zinc Hyaluronate and Hyanutra-RH Hair Nourishing Shield won Fountain Awards
Details :
Product Name : Hybloom
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2023
Lead Product(s) : Zinc Hyaluronate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ectoine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bloomecto™ Ectoine -- Nasal Spray New Solution
Details :
Product Name : Bloomecto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2022
Lead Product(s) : Ectoine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Helicobacter Pylori
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
2022 FIC Exhibition | Bloomage Biotech Launches AbateHP™- the New Anti-Helicobacter Pylori Solution
Details : AbateHP™, Bloomage Biotech fully demonstrated the application of sodium hyaluronate in oral beauty, bone and joint maintenance, intestinal health and other fields.
Product Name : AbateHP
Product Type : Microorganism
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Helicobacter Pylori
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Rohto Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Chinese Company Bloomage Biotech Forges Partnership with Japanese Firms on Regenerative Medicine
Details : RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 24, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Rohto Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Recipient : Bloomage Biotechnology Corp., Ltd
Deal Size : Undisclosed
Deal Type : Termination
Medytox’s Chinese Partner Terminates BTX Deal
Details : Medytox applied for a license for Meditoxin (export name: Neuronox having Clostridium Botulinum Toxin type A), Medytox’s BTX product, to China’s National Medical Products Administration in February 2018.
Product Name : Neuronox
Product Type : Protein
Upfront Cash : Undisclosed
April 08, 2022
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Recipient : Bloomage Biotechnology Corp., Ltd
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyanutra™ RH Hair Nourishing Shield-Innovation Hyaluronic Acid Hair Care Solution
Details :
Product Name : Hyanutra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2022
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable